Retesting for latent tuberculosis in patients with inflammatory bowel disease after exposure to biologics
P Papay, C Primas, A Eser, G Novacek, S Winkler, S Frantal, S Angelberger, A Mikulits, C Dejaco, H Vogelsang, W Reinisch · Zeitschrift für Gastroenterologie · 2012 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background/Aim: Patients treated with TNF-α inhibitors (TNFi) are at high risk of reactivation of latent tuberculosis (LTB). Prospective studies on monitoring of TB reactivation and/or infection in this risk group are lacking. Methods: We retested consecutive patients with inflammatory bowel disease (IBD) under TNFi therapy for a minimum of 5 months for LTB by interferon-γ release assay (IGRA) and tuberculin skin test (TST). From each subject detailed patient history and concomitant therapy were captured. Results: After a median of 34.9 weeks (20.7–177.7) IGRA was retested in 184/227 patients (81.1%; Crohn's dis…
